Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery platform and services for its ecosystem of 100+ global partners Boston, MA, USA and Basel, Switzerland, December 9th, 2021 – Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and […]
Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
Alloy Therapeutics and Pyxis Oncology launched Voxall Therapeutics, a joint venture focused on developing novel immune-modulating antibody therapies for cancer and autoimmune diseases. The collaboration integrates Alloy’s ATX-Gx™ discovery platform with Pyxis’ target expertise and preclinical capabilities, facilitated by Alloy’s 82VS venture studio. LEXINGTON & CAMBRIDGE, Mass., May 25th, 2021 – Alloy Therapeutics (“Alloy”) and […]